Dashboard
Manage Tickers

LGVN Longeveron Inc.

Nasdaq longeveron.com


$ 0.79 $ 0.03 (3.52 %)    

Monday, 20-Oct-2025 16:37:59 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 611.56 $ 0.00 (0 %)
DIA $ 467.27 $ 0.00 (0 %)
SPY $ 671.44 $ 0.00 (0 %)
TLT $ 91.63 $ 0.00 (0 %)
GLD $ 391.58 $ 0.00 (0 %)
$ 0.8056
$ 0.80
$ 0.78 x 52,250
$ 0.85 x 2,569
-- - --
$ 0.63 - $ 2.48
251,598
na
12.09M
$ 0.89
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-13-2025 06-30-2025 10-Q
2 05-08-2025 03-31-2025 10-Q
3 02-28-2025 12-31-2024 10-K
4 11-12-2024 09-30-2024 10-Q
5 08-14-2024 06-30-2024 10-Q
6 05-14-2024 03-31-2024 10-Q
7 02-27-2024 12-31-2023 10-K
8 11-09-2023 09-30-2023 10-Q
9 08-11-2023 06-30-2023 10-Q
10 05-12-2023 03-31-2023 10-Q
11 03-14-2023 12-31-2022 10-K
12 11-14-2022 09-30-2022 10-Q
13 08-12-2022 06-30-2022 10-Q
14 05-13-2022 03-31-2022 10-Q
15 03-11-2022 12-31-2021 10-K
16 11-12-2021 09-30-2021 10-Q
17 08-13-2021 06-30-2021 10-Q
18 05-14-2021 03-31-2021 10-Q
19 03-30-2021 12-31-2020 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

longeveron-entered-into-sales-agreement-for-sale-of-shares-of-class-a-common-stock-for-up-to-107m-from-time-to-time
Longeveron Entered Into Sales Agreement Fo...
09/19/2025 20:48:09

-SEC Filing

longeveron-appoints-than-powell-as-interim-chief-executive-officer-effective-immediately-dr-joshua-hare-appointed-as-executive-chairman-of-the-board
Longeveron Appoints Than Powell As Interim...
09/03/2025 20:14:03

MIAMI, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN), a clinical stage regenerative medicine biotechnology c...

roth-capital-maintains-buy-on-longeveron-lowers-price-target-to-3
Roth Capital Maintains Buy on Longeveron, ...
08/15/2025 17:27:32

Roth Capital analyst Boobalan Pachaiyappan maintains Longeveron (NASDAQ:LGVN) with a Buy and lowers the price target from $1...

longeveron-q2-eps-033-beats-035-estimate-sales-316000k-miss-414650k-estimate
Longeveron Q2 EPS $(0.33) Beats $(0.35) Es...
08/13/2025 20:40:47

Longeveron (NASDAQ:LGVN) reported quarterly losses of $(0.33) per share which beat the analyst consensus estimate of $(0.35) by...

Core News & Articles
Earnings Scheduled For August 13, 2025
08/13/2025 08:32:30

preview-longeverons-earnings
Preview: Longeveron's Earnings
08/12/2025 18:01:38

longeveron-shares-resume-trade-following-circuit-breaker-halt
Longeveron Shares Resume Trade Following C...
08/08/2025 17:35:40

longeveron-prices-offering-of-588m-shares-and-147m-accompanying-short-term-warrants-at-085-expected-to-be-5m-potential-additional-gross-proceeds-to-the-company-from-the-short-term-warrants-if-fully-exercised-on-a-cash-basis-will-be-125m
Longeveron Prices Offering Of 5.88M Shares...
08/08/2025 17:32:41

Longeveron Inc. (NASDAQ:LGVN) ("Longeveron" or "Company"), a clinical stage regenerative medicine biotechnology...

Core News & Articles
12 Health Care Stocks Moving In Tuesday's ...
08/05/2025 12:08:30

Core News & Articles
12 Health Care Stocks Moving In Monday's A...
08/04/2025 21:07:07

longeveron-licenses-issued-us-patent-for-stem-cell-technology-from-university-of-miami
Longeveron Licenses Issued US Patent For S...
07/21/2025 13:16:12

Longeveron has licensed issued US Patent 12,168,028 B2, entitled "Methods for obtaining cardiomyogenic precursor cells"...

watching-longeveron-zacks-small-cap-reiterates-955-price-valuation-originally-stated-on-june-24-2025
Watching Longeveron; Zacks Small-Cap Reite...
07/08/2025 16:14:37

https://s27.q4cdn.com/906368049/files/News/2025/Zacks_SCR_Research_07082025_LGVN_Sorensen.pdf

longeveron-announces-fda-approval-of-ind-application-for-stem-cell-therapy-laromestrocel-as-potential-treatment-for-pediatric-dilated-cardiomyopathy
Longeveron Announces FDA Approval Of IND A...
07/08/2025 13:17:04

Accepted IND application allows for development program to move directly to a Phase 2 pivotal registration clinical trialPhase ...

watching-longeveron-zacks-small-cap-research-gives-stock-955-price-valuation
Watching Longeveron; Zacks Small-Cap Resea...
06/24/2025 15:07:46

https://scr.zacks.com/files/News/2025/Zacks_SCR_Research_06242025_LGVN_Sorensen.pdf

longeveron-completes-enrollment-of-phase-2b-clinical-trial-evaluating-investigational-cellular-therapy-laromestrocel-as-potential-adjunct-treatment-for-hypoplastic-left-heart-syndrome
Longeveron Completes Enrollment Of Phase 2...
06/24/2025 10:31:54

Top-line trial results are anticipated in the third quarter of 2026, after the final follow-up at 12-monthsLaromestrocel Biolog...

longeveron-q1-eps-034-misses-030-estimate-sales-38100k-miss-60825k-estimate
Longeveron Q1 EPS $(0.34) Misses $(0.30) E...
05/08/2025 20:37:52

Longeveron (NASDAQ:LGVN) reported quarterly losses of $(0.34) per share which missed the analyst consensus estimate of $(0.30) ...

Core News & Articles
Earnings Scheduled For May 8, 2025
05/08/2025 08:33:13

longeveron-issues-letter-to-shareholders
Longeveron Issues Letter To Shareholders
04/22/2025 20:12:21

Dear Fellow Shareholders,Twenty twenty-four was a year of execution for Longeveron. We made significant progress advancing Long...

longeveron-files-for-mixed-shelf-of-up-to-70m
Longeveron Files For Mixed Shelf Of Up To ...
03/28/2025 20:41:02

- SEC Filing

hc-wainwright--co-reiterates-buy-on-longeveron-maintains-10-price-target
HC Wainwright & Co. Reiterates Buy on Long...
03/21/2025 12:32:45

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Longeveron (NASDAQ:LGVN) with a Buy and maintains $10 price ta...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION